Drug intelligence / Profile preview

shegan zhike

Development stage: Unknown
Lead developer: Liaoning Provincial Academy of Traditional Chinese Medicine
Administration: Oral

Overview

Shegan Zhike is a Traditional Chinese Medicine (TCM) botanical drug candidate developed as a capsule for the treatment of post-infectious cough. The formulation is based on traditional herbal knowledge, likely featuring *Belamcanda chinensis* (Shegan) as a key component, which is traditionally utilized for its antitussive, expectorant, and anti-inflammatory properties. It is currently undergoing Phase I clinical evaluation in China to assess its safety and tolerability in healthy human subjects. The development is sponsored by the Liaoning Provincial Academy of Traditional Chinese Medicine, also known as the Affiliated Second Hospital of Liaoning University of Traditional Chinese Medicine.

Other names: Shegan Zhike Capsules射干止咳胶囊

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on shegan zhike.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shegan zhike.

Explore the full profile